PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
174 hedge funds and large institutions have $304M invested in PDL BioPharma, Inc. in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 48 increasing their positions, 60 reducing their positions, and 30 closing their positions.
12% more call options, than puts
Call options by funds: $342K | Put options by funds: $306K
10% more capital invested
Capital invested by funds: $276M → $304M (+$28.1M)
8% less funds holding
Funds holding: 190 → 174 (-16)
20% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 60
33% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$31.7M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$7.29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.41M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.1M |
| 5 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
+$2.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$4.31M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$2.88M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$2.5M |
| 4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$2.23M |
| 5 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$2.17M |
PDLI Hedge Fund Activity: Q1 2017 in Review
174 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2017, worth a combined $304M — up 10% from $276M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PDLI and 20 opened new positions — a net loss of 10 holders — while 60 trimmed existing stakes and 48 added.
The largest buyer was BlackRock, adding an estimated $31.7M. The largest seller was Robeco Institutional Asset Management, cutting an estimated $4.31M.
- 174 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2017, down from 190 in Q4 2016.
- Funds reported $304M of PDL BioPharma, Inc. stock for Q1 2017, up 10% quarter-over-quarter.
- 20 funds opened new PDL BioPharma, Inc. positions in Q1 2017 and 30 closed out, a net change of -10 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2017 was BlackRock, an estimated $31.7M added.
- The largest PDL BioPharma, Inc. seller in Q1 2017 was Robeco Institutional Asset Management, an estimated $4.31M sold.
Based on aggregated 13F filings for Q1 2017.